AMCP 2022 to Feature New Outcomes Research from Analysis Group
March 29, 2022
Analysis Group’s HEOR, Epidemiology & Market Access practice will present 13 posters, including four Encore presentations, at the the Academy of Managed Care Pharmacy’s (AMCP’s) 2022 Meeting, which will be held March 29–April 1, 2022, in Chicago, IL. One of the abstracts received a gold medal honor, and two received silver medal honors.
Gold medal
- “Prevalence and Incidence of Alopecia Areata in the US Employer-Sponsored Insured Population: A Real-World Data Analysis,” coauthored by an Analysis Group team – including Vice President Elyse Swallow, Managers Wei Gao and Nicolae Done, and Senior Analysts Christopher Carley and Travis Wang – in collaboration with a team from Pfizer.
Silver medal
- “Impact of Different Long-Acting Injectable Antipsychotic Event-Driven Initiation Strategies on Clinical Outcomes Among Different Demographic Groups of Medicaid Beneficiaries with Schizophrenia,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Marie-Hélène Lafeuille, Manager Bruno Émond, Associate Laura Morrison, and Senior Research Professional Isabelle Ghelerter – in collaboration with a team from Janssen Scientific Affairs.
- “Economic Burden among Sjögren’s Patients in an Integrated Delivery Network in the United States,” coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Manager Irina Pivneva, and Associate Carmine Rossi – in collaboration with a team from Novartis Pharmaceuticals.
Additional poster presentations include:
- “Health Care Resource Utilization and Cost Among Patients with Advanced/Recurrent Endometrial Cancer in the United States,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Marie-Hélène Lafeuille, Manager Bruno Émond, and Senior Research Professional Isabelle Ghelerter – in collaboration with a team from GlaxoSmithKline.
- “Healthcare Resource Use Before and After the Initiation of Prucalopride Treatment: A Real-World Study in Patients with Constipation in the USA,” coauthored by an Analysis Group team – including Vice Presidents Rajeev Ayyagari and Emi Terasawa – in collaboration with a team from Takeda Pharmaceuticals USA.
- “Health Care Costs Before and After the Initiation of Prucalopride Treatment: A Real-World Study in Patients with Constipation in the USA,” coauthored by an Analysis Group team – including Vice Presidents Rajeev Ayyagari and Emi Terasawa – in collaboration with a team from Takeda Pharmaceuticals USA.
- “Projecting the Economic Outcomes of Switching Patients with Schizophrenia from Oral Atypical Antipsychotics to Once-Monthly, Once-Every-Three-Months, and Once-Every-Six-Months Paliperidone Palmitate,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Associate Laura Morrison, and Senior Research Professionals Isabelle Ghelerter and Maude Vermette-Laforme – in collaboration with a team from Janssen Scientific Affairs.
- “Attainment of Early, Deep Prostate-Specific Antigen Response in Metastatic Castration-Sensitive Prostate Cancer: A Comparison of Patients Initiated on Apalutamide or Enzalutamide,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Associate Carmine Rossi, and Senior Research Professional Frederic Kinkead – in collaboration with a team from Janssen Scientific Affairs.
- “Economic Burden and Treatment Patterns in Patients with Type 2 Diabetes and Chronic Kidney Disease,” coauthored by an Analysis Group team – including Vice Presidents Keith Betts and Jinlin Song and Senior Analyst Karen Yang – in collaboration with a team from Bayer Healthcare US.
Encore presentations include:
- “Treatment Patterns Among Patients (pts) with Advanced/Recurrent Endometrial Cancer (EC) in the United States,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Marie-Hélène Lafeuille, Manager Bruno Émond, and Senior Research Professional Isabelle Ghelerter – in collaboration with a team from GlaxoSmithKline.
- “Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population,” coauthored by an Analysis Group team – including Managing Principals Mei Sheng Duh and Mihran Yenikomshian, Vice President Wendy Cheng, and Senior Research Professional Malena Mahendran – in collaboration with a team from Apellis Pharmaceuticals.
- “Health Care Resource Utilization and Associated Costs of Cytomegalovirus Management Among Solid Organ Transplant Recipients,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Wendy Cheng, and Manager Philippe Thompson-Leduc – in collaboration with a team from Takeda Development Center Americas.
- “Economic Burden and Treatment Patterns of Cytomegalovirus Management Following Solid Organ Transplant,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Wendy Cheng, and Manager Philippe Thompson-Leduc – in collaboration with a team from Takeda Development Center Americas.